Your browser doesn't support javascript.
loading
Pilot of three objective markers of physical health and chemotherapy toxicity in older adults.
Hsu, T; Chen, R; Lin, S C X; Djalalov, S; Horgan, A; Le, L W; Leighl, N.
Afiliación
  • Hsu T; University of Toronto, Toronto, ON;
  • Chen R; University of Toronto, Toronto, ON;
  • Lin SC; Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON;
  • Djalalov S; Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON;
  • Horgan A; Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON;
  • Le LW; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON.
  • Leighl N; Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON;
Curr Oncol ; 22(6): 385-91, 2015 Dec.
Article en En | MEDLINE | ID: mdl-26715870
ABSTRACT

BACKGROUND:

Patient function is a key part of the clinical decision to offer chemotherapy and has, in earlier studies, been associated with chemotherapy toxicity. Objective testing might be more accurate than patient-reported or physician-assessed physical function, and thus might be a stronger predictor of chemotherapy toxicity in older adults.

METHODS:

Patients, 70 years of age and older, with thoracic or colorectal cancer were recruited. Three physical tests were performed before commencement of a new line of chemotherapy grip strength, 4-m walk test, and the Timed Up and Go (tug). Our pilot study explored the association between those tests and chemotherapy toxicity.

RESULTS:

The 24 patients recruited had a median age of 74.5 years (range 70-84 years), and 54.2% had an Eastern Cooperative Oncology Group performance status of 0 or 1. Median score on the Charlson comorbidity index was 1 (range 0-4). Almost two thirds had metastatic disease, 70% were chemonaïve, and 83.3% were about to receive polychemotherapy. Patients had a mean tug of 13.2 ± 5.7 s and a mean gait speed of 0.74 ± 0.24 m/s; 50% had a grip strength test in the lowest 20th percentile. Grades 3-5 chemotherapy toxicities occurred in 34.7% of the patients; two thirds required a dose reduction or delay; and one third discontinued chemotherapy because of toxicity. Hospitalization attributable to chemotherapy was uncommon (12.5%). A trend toward increased severe chemotherapy toxicity with slower gait speed was observed (p = 0.049).

CONCLUSIONS:

Abnormalities in objective markers of physical function are common in older adults with cancer, even in those deemed fit for chemotherapy. However, those abnormalities were not associated with an increased likelihood of chemotherapy toxicity in the population included in this small pilot study.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Curr Oncol Año: 2015 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Curr Oncol Año: 2015 Tipo del documento: Article